Nutritional supplements and extracts like Cranesbill have benefits and are used by cancer patients and those at-genetic risk of cancer. There is limited or hardly any clinical data available for use of nutritional supplements and foods in cancer patients. Generating clinical evidence of efficacy for cancer through a randomized clinical trial is further infeasible due to variations in genetics and cancer chemotherapy treatments across cancer patients. Hence a different and new approach is needed to find out for which cancers you should not take Cranesbill supplement and why should not take them?
Is it okay to take Cranesbill extracts or supplements for all cancer indications and any chemotherapy treatment? A common belief but a myth is that everything natural can only be of benefit and do no harm. For example, the use of grapefruit with certain medications is not recommended. Another example is the use of spinach with some blood thinning medications can cause adverse interactions and hence to be avoided. For cancer, nutrition including plant-based foods and supplements can influence outcomes and hence an extremely important decision which needs to be made. Hence NIH-National Cancer Institute has a website for nutrition for cancer care for patients which are generalized recommendations and not personalized for cancer indication and treatments.
A frequently asked question by cancer patients and those at-risk is “What Foods and Nutritional Supplements could be beneficial over others for me?”. “Who should not take an extract or supplement and why?”. Generic guidelines like eating only plant-based-foods or avoiding all sugar or adopting a keto diet is a good start but not actionable and personalized enough.
To find answers to questions on extracts and nutritional supplements and foods requires knowledge of contained active ingredients; genetic mutation prevalence for cancer indication; understanding of underlying cancer biology; chemotherapy treatments and mechanism of actions of active ingredients.
Taking Cranesbill extracts or nutritional supplements may benefit Primary Monoclonal gammopathy of undetermined significance patients on Lenalidomide treatment over Vitamin A nutritional supplements. But Cranesbill supplements or Cranesbill extracts offer less benefit if on Cyclophosphamide treatment for Primary Gastrointestinal Neuroendocrine Tumors compared to Ferulic Acid. Similarly, taking nutritional supplements Cranesbill may benefit healthy individuals who are at genetic risk of cancer due to mutation of gene B2M over Gotu Kola. But avoid nutritional supplements Cranesbill when at genetic risk of cancer due to mutation of gene TP53.
The takeaway being – cancer, genomics, treatments and other personalized factors will influence decision making to questions like: Are extracts or nutritional supplements Cranesbill beneficial and should not be taken? Why should Cranesbill be not taken? Who should not take Cranesbill? What are side effects of Cranesbill with Cyclophosphamide chemotherapy? What are the benefits of Cranesbill for cancer? Can Cranesbill help fight cancer and so on.
Whenever there are changes in chemotherapy treatments or cancer tissue genetics – the nutrition may change and hence needs to be re-evaluated. Do consider factors like cancer indication, ongoing chemotherapy treatments and nutritional supplements, age, gender, weight, height, lifestyle and genetics for personalization of nutrition.
Use of nutritional supplements – vitamins, herbs, minerals, probiotics, and other specialty categories are increasing. Supplements are high concentrations of active ingredients which are also found in different foods. Difference between supplements and foods being that foods contain more than one active ingredient at much lower concentrations. Every active ingredient in an extract or nutritional supplement or food has a unique mechanism of action which can influence nutrition decisions.
These are some example questions which nutrition planning should help answer for you. Should you take supplements Cranesbill? Should you take it when at genetic risk of cancer for mutation of gene B2M? Should you take it when at genetic risk of cancer for mutation of gene TP53? Should you take it when diagnosed with Primary Gastrointestinal Neuroendocrine Tumors? Should you take it when diagnosed with Primary Monoclonal gammopathy of undetermined significance? Should you take it when on Lenalidomide treatment? Should you continue taking it if you change your treatment from Lenalidomide to Cyclophosphamide? So a general explanation like – it is organic and plant-based or it increases immunity is not sufficient information for making a decision of use of Cranesbill extracts and nutritional supplements.
Genetic variations across cancer patients can be different and hence no two cancers are alike. The improved availability of “personalized to genetics” chemotherapy treatments and cancer disease monitoring via blood and saliva have been significant factors to improve outcomes. The earlier the lifestyle and treatment intervention – the better the influence on outcome. Genetic testing has the potential to assess cancer risk and susceptibility early. But for at-risk individuals besides regular monitoring in most cases there are no therapeutic treatment intervention options available. After diagnosis with cancer such as Primary Monoclonal gammopathy of undetermined significance or Primary Gastrointestinal Neuroendocrine Tumors, the treatments get personalized to tumor genomics and factors like staging of disease, age and gender. During cancer remission (after treatment cycle is complete) – monitoring is used for assessment of any relapse and accordingly decide on next steps. A large majority of cancer patients and those at-risk may take nutritional supplements like Cranesbill.
So the question is that are all genetic risks and cancer indications to be considered uniformly when making decisions on the use of Cranesbill extracts or nutritional supplements? Are the biochemical pathway implications of genetic risk for cancer due to mutation of gene B2M the same as due to mutation of gene TP53? Are the implications of Primary Monoclonal gammopathy of undetermined significance the same as Primary Gastrointestinal Neuroendocrine Tumors? Is it one and the same if you are on treatment with Cyclophosphamide or Lenalidomide?
Cranesbill – An Extract or Nutritional Supplement
Cannabigerol (CBG) is one of the phytocannabinoids present in Cannabis sativa plants. It is the precursor to other cannabinoids. It is also considered to have anti-cancer properties. Following are some of the potential benefits of Cannabigerol (CBG) :
- May have antibacterial properties (Giovanni Appendino et al, J Nat Prod., 2008)
- May have neuroprotective effects (Sara Valdeolivas et al, Neurotherapeutics., 2015)
- May help increase appetite (Daniel I Brierley et al, Psychopharmacology (Berl)., 2016)
- May help reduce inflammation related to Inflammatory Bowel Diseases (Francesca Borrelli et al, Biochem Pharmacol., 2013)
- May help reduce contractions in bladder (Ester Pagano et al, Nat Prod Commun., 2015)
Cranesbill supplements contain many active ingredients including Geraniin at different concentration levels. The molecular pathways which are regulated by Cranesbill include Cell Survival, Oxidative Stress and NFKB Signaling. These biochemical pathways directly or indirectly regulate specific cancer molecular endpoints like growth, spread and death of cancer cells. Because of this biological regulation – for cancer nutrition, the right choice of supplements like Cranesbill individually or in combination is an important decision to be made. When making decisions on the use of supplement Cranesbill over other nutritional supplements – do consider all these factors.
Who Should not take Cranesbill Supplements and Why?
There is no easy way to answer the question “For which cancers should I not chooseCranesbill nutritional supplements”. Just like the same chemotherapy treatment does not work across patients, for similar reasons Cranesbill in comparison with other nutritional supplements may be beneficial or not. Along with which cancer and associated genetics – the ongoing treatments, lifestyle habits, height, weight and food allergies are all factors in deciding if Cranesbill should be avoided or not and why.
1. Will Cranesbill Supplements benefit Primary Gastrointestinal Neuroendocrine Tumors patients undergoing Cyclophosphamide treatment?
Primary Gastrointestinal Neuroendocrine Tumors is characterized and driven by specific genetic mutations like ALK, APC and DAXX leading to biochemical pathway changes in Oxidative Stress, Growth Factor Signaling, JAK-STAT Signaling, Angiogenesis, Androgen Signaling and Apoptosis. A cancer treatment like Cyclophosphamide works through a specific pathway mechanism of action. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach which is effective. In such a condition any food or nutritional supplement which has a contrary effect to the treatment or reduces the overlap should be avoided. As an example, Cranesbill supplement should not be taken for Primary Gastrointestinal Neuroendocrine Tumors along with treatment Cyclophosphamide. Cranesbill supplement impacts the biochemical pathway called Oxidative Stress which either promotes drivers of the disease and/or nullifies the treatment effect. Some of the factors which should be considered when choosing nutrition are type of cancer, treatments and supplements being taken currently (if any
2. Will Cranesbill Supplements benefit Primary Monoclonal gammopathy of undetermined significance Patients undergoing Lenalidomide Treatment?
Primary Monoclonal gammopathy of undetermined significance is characterized and driven by specific genetic mutations like LATS2, ZMYM2 and CDK8 leading to biochemical pathway changes in Cell Survival and Hippo Signaling. A cancer treatment like Lenalidomide works through specific pathway mechanisms. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach. In such a condition any food or nutritional supplement which supports treatment action or improves the overlap should be considered. As an example, Cranesbill supplements should be considered for Primary Monoclonal gammopathy of undetermined significance along with the treatment Lenalidomide. Cranesbill supplement benefits impacts pathways/processes like Cell Survival which either obstruct drivers of Primary Monoclonal gammopathy of undetermined significance and/or improve Lenalidomide treatment effect.
Foods to Eat After Cancer Diagnosis!
No two cancers are the same. Go beyond the common nutrition guidelines for everyone and make personalized decisions about food and supplements with confidence.
3. What about Cranesbill Supplements for Healthy Individuals with TP53 Mutation associated Genetic Risk?
Different companies offer panels of genes to be tested for assessing genetic risk to different cancers. These panels cover genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system and others. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant may also guide testing and diagnosis of at-risk relatives. TP53 is one of the genes generally available in panels for cancer risk testing.
TP53 mutation causes biochemical pathways/processes like Oxidative Stress, Cell Cycle Checkpoints and Apoptosis to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Cranesbill should not be taken when the genetic panel identifies mutation of TP53 for Lung Cancer. Cranesbill impacts pathways/processes like Oxidative Stress and creates adverse conditions with TP53.
4. What about Cranesbill Supplements for Healthy Individuals with B2M Mutation associated Genetic Risk?
B2M is one of the genes available in panels for cancer risk testing. B2M mutation causes biochemical pathways/processes like NFKB Signaling and Antigen Presentation to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Cranesbill supplements may be considered when the genetic panel identifies mutations in B2M for Diffuse Large B-cell Lymphoma. Cranesbill impacts pathways/processes like NFKB Signaling and creates a canceling effect in those individuals with B2M mutation.
* Other Factors are also included like BMI, Treatments, Lifestyle Habits
It is important to remember that cancer chemotherapy treatments and nutrition are never the same for everyone. Food and nutritional supplements like Cranesbill are chosen by you and can influence outcomes.
“What should I eat?” is a commonly asked question by cancer patients and those at-risk. The answer to this question depends on cancer indication, underlying genetics, current chemotherapy treatments, food allergies, lifestyle information, and food preferences.
The addon.life approach to nutrition personalization uses knowledge of active ingredients contained in foods and nutritional supplements, cancer biology, chemotherapy treatment action and genetic mutation prevalence across cancer indications. addon.life team of clinicians, clinical scientists and engineers are experts in cancer biology focusing only on nutrition personalization for cancer patients and those at-risk.
What food you eat and which supplements you take is a decision you make. Your decision should include consideration of the cancer gene mutations, which cancer, ongoing treatments and supplements, any allergies, lifestyle information, weight, height and habits.
The nutrition planning for cancer from addon is not based on internet searches. It automates the decision making for you based on molecular science implemented by our scientists and software engineers. Irrespective of whether you care to understand the underlying biochemical molecular pathways or not - for nutrition planning for cancer that understanding is needed.
Get started NOW with your nutrition planning by answering questions on the name of cancer, genetic mutations, ongoing treatments and supplements, any allergies, habits, lifestyle, age group and gender.
- Identification of the plant compound geraniin as a novel Hsp90 inhibitor.
- Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages.
- cBioPortal for Cancer Genomics
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
- Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion.
- Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
Personalized Nutrition for Cancer!
Cancer changes with time. Customize and modify your nutrition based on cancer indication, treatments, lifestyle, food preferences, allergies and other factors.